北京大学学报(医学版) ›› 2016, Vol. 48 ›› Issue (3): 502-506. doi: 10.3969/j.issn.1671-167X.2016.03.022

• 论著 • 上一篇    下一篇

甲状腺乳头状癌中BRAF基因突变与中央区淋巴结转移的关系及临床意义

张玉洁,刘宝国△,赵治艳,盛今东,冯冬冬   

  1. (北京大学临床肿瘤学院,北京肿瘤医院暨北京市肿瘤防治研究所头颈外科,恶性肿瘤发病机制及转化研究教育部重点实验室,北京100142)
  • 出版日期:2016-06-18 发布日期:2016-06-18
  • 通讯作者: 刘宝国 E-mail:lbg29@163.com
  • 基金资助:

     国家高技术研究发展计划(863计划,2012AA02A210)资助

Relationship and clinical significance between mutated BRAF with prophylactic central-neck nodal dissection in papillary thyroid carcinoma

ZHANG Yu-jie, LIU Bao-guo△, ZHAO Zhi-yan, SHENG Jin-dong, FENG Dong-dong   

  1. [Department of Head & Neck, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China]
  • Online:2016-06-18 Published:2016-06-18
  • Contact: LIU Bao-guo E-mail:lbg29@163.com
  • Supported by:

    Supported by the National High Technology Research and Development Program of China (863 Program, 2012AA02A202)

摘要:

目的:阐明BRAF基因突变在甲状腺乳头状癌中央区淋巴结转移中的作用。方法:采集整理2012年至2014年间于北京大学肿瘤医院头颈外科行手术治疗的275例甲状腺乳头状癌患者,对其肿瘤组织进行BRAF基因检测并通过单因素、多因素Logistic回归模型探索中央区(Ⅵ区)淋巴结转移的危险因素。结果:275例患者中,女性224例(81.5%),男性51例(18.5%)。有57.8%(159/275)的患者发生中央区淋巴结转移,BRAF的突变率为53.8%(148/275),其中,超声下有无钙化(ORadjusted=1.47,95%CI:1.10~1.98,P=0.01)、肿瘤的长径(ORadjusted=1.48,95%CI:1.04~2.30,P=0.048)及患者的年龄(ORadjusted=1.48,95%CI:1.04~2.30,P=0.048)与淋巴结转移显著相关。分层分析后,BRAF突变在超声下边界尚清组(ORadjusted=3.19,95%CI:1.18~9.43,P=0.023)和超声下无钙化组(ORadjusted=4.84,95%CI:1.68~13.84,P=0.003)均与淋巴结转移正相关。结论:甲状腺乳头状癌患者具有一定比例的中央区淋巴结转移率,BRAF突变是甲状腺乳头状癌的特征性分子事件,钙化、低年龄组及肿瘤长径较长的患者更易发生中央区淋巴结转移。尽管超声下边界尚清或无钙化,但一旦合并BRAF突变则更易发生淋巴结转移,中央区淋巴结清扫术是有效的治疗方法。

关键词: 甲状腺癌, 乳头状, 淋巴转移, BRAF, 突变, 淋巴结切除术

Abstract:

Objective: To evaluate the molecular diagnosis marker of papillary thyroid carcinoma (PTC), the relationship between lymphatic metastasis of central neck compartment PTC, and the operation indication of prophylactic central neck dissection. Methods: We conducted a retrospective study, including 275 PTC patients and detected their BRAF mutation rates during 2012 and 2014 and explored the risk factors of the central node lymphatic metastasis by Logistic regression model. Results: Of the 275 PTC patients, 224 (81.5%) were female and 51 (18.5%) were male. BRAF mutational rates were 53.8% (148/275) and lymphatic metastasis 57.8% (159/275). Multivariate analysis showed calcification (ORadjusted=1.47, 95%CI: 1.10-1.98, P=0.01), tumor diameter (ORadjusted=1.48, 95%CI: 1.04-2.30, P=0.048) and age (ORadjusted=1.48, 95%CI: 1.04-2.30, P=0.048) were associa-ted with lymphatic metastasis. In stratified analysis, BRAF mutation (ORadjusted=3.19, 95%CI: 1.18-9.43, P=0.023) in clear boarder group and BRAF mutation (ORadjusted=4.84, 95%CI: 1.68-13.84, P=0.003) in calcification group were more likely to have lymphatic metastases. Conclusion: Central neck metastasis takes up a high ratio in papillary thyroid cancer patients, BRAF mutation in papillary thyroid carcinoma is a characteristic molecular event. Furthermore, patients with calcification under ultrasound detection, lower age group and longer tumor diameter are more susceptible to suffer central neck metastasis. Especially for stratified analysis, non-calcified  BRAF mutation or BRAF mutation with clear border under ultrasound detection are more susceptible to suffer central neck metastasis, and radical prophylactic central neck dissection should be carried on for these patients.

Key words: Thyroid cancer, papillary, Lymphatic metastasis, BRAF, Mutation, Lymph node excision

中图分类号: 

  • R736.1
[1] 方杨毅,李强,黄志高,陆敏,洪锴,张树栋. 睾丸鞘膜高分化乳头状间皮肿瘤1例[J]. 北京大学学报(医学版), 2024, 56(4): 741-744.
[2] 金银姬,孙琳,赵金霞,刘湘源. 血清IgA型抗鼠科肉瘤病毒癌基因同源物B1抗体在类风湿关节炎中的意义[J]. 北京大学学报(医学版), 2023, 55(4): 631-635.
[3] 时云飞,王豪杰,刘卫平,米岚,龙孟平,刘雁飞,赖玉梅,周立新,刁新婷,李向红. 血管免疫母细胞性T细胞淋巴瘤临床与分子病理学特征分析[J]. 北京大学学报(医学版), 2023, 55(3): 521-529.
[4] 熊焰,张波,聂立功,吴世凯,赵虎,李东,邸吉廷. 胸部SMARCA4缺失性未分化肿瘤的病理诊断与联合免疫检测点抑制剂治疗[J]. 北京大学学报(医学版), 2023, 55(2): 351-356.
[5] 周秋君,龚潘,焦莶如,杨志仙. 1例Angelman综合征合并眼皮肤白化病2型患者的临床和遗传学分析及文献回顾[J]. 北京大学学报(医学版), 2023, 55(1): 181-185.
[6] 程晓静,蒋栋,张连海,王江华,李雅真,翟佳慧,闫宝琪,张露露,谢兴旺,李子禹,季加孚. KRAS G12V特异性T细胞受体治疗恶性肿瘤的临床前研究[J]. 北京大学学报(医学版), 2022, 54(5): 884-895.
[7] 博尔术,洪鹏,张宇,邓绍晖,葛力源,陆敏,李楠,马潞林,张树栋. 乳头状肾细胞癌的临床病理特征和预后分析[J]. 北京大学学报(医学版), 2022, 54(4): 615-620.
[8] 秦彩朋,宋宇轩,丁梦婷,王飞,林佳兴,杨文博,杜依青,李清,刘士军,徐涛. 肾癌免疫治疗疗效评估突变预测模型的建立[J]. 北京大学学报(医学版), 2022, 54(4): 663-668.
[9] 陈曦,王斯悦,薛恩慈,王雪珩,彭和香,范梦,王梦莹,武轶群,秦雪英,李劲,吴涛,朱洪平,李静,周治波,陈大方,胡永华. 基于核心家系全外显子组测序数据探索新生突变与非综合征型唇腭裂的关联[J]. 北京大学学报(医学版), 2022, 54(3): 387-393.
[10] 叶剑飞,赵磊,王国良,洪锴,马潞林. 睾丸横纹肌肉瘤的诊治分析[J]. 北京大学学报(医学版), 2021, 53(6): 1178-1182.
[11] 洪鹏,田晓军,赵小钰,杨飞龙,刘茁,陆敏,赵磊,马潞林. 肾移植术后双侧乳头状肾癌1例[J]. 北京大学学报(医学版), 2021, 53(4): 811-813.
[12] 曹泽,王乐童,刘振明. 严重急性呼吸综合征冠状病毒2的Spike蛋白点突变后与受体蛋白质及潜在抗病毒药物结合能力的同源建模分析[J]. 北京大学学报(医学版), 2021, 53(1): 150-158.
[13] 吴君怡,余淼,孙仕晨,樊壮壮,郑静蕾,张刘陶,冯海兰,刘洋,韩冬. 少汗性外胚层发育不良患者EDA基因突变检测及表型分析[J]. 北京大学学报(医学版), 2021, 53(1): 24-33.
[14] 武颖超,蔡云龙,戎龙,张继新,刘金,汪欣. 早期胃癌淋巴结转移规律及内镜黏膜下剥离术治疗早期胃癌的疗效评价[J]. 北京大学学报(医学版), 2020, 52(6): 1093-1097.
[15] 鲍轶,莫娟芬. 同时性多原发肺腺癌组织编码转录因子ERG基因相同位点突变1例报告[J]. 北京大学学报(医学版), 2020, 52(5): 971-974.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!